期刊
CANCERS
卷 11, 期 5, 页码 -出版社
MDPI
DOI: 10.3390/cancers11050726
关键词
breast cancer; epigenetics; epithelial to mesenchymal transition; signal transduction; SMAD; TGF-beta
类别
资金
- European Union Horizon 2020 Research and Innovation Programme with a Marie Sklodowska-Curie Individual Fellowship [786880]
- Cancer Genomics Centre Netherlands (CGC.nl)
- Marie Curie Actions (MSCA) [786880] Funding Source: Marie Curie Actions (MSCA)
The Transforming Growth Factor-beta (TGF-beta) signaling pathway has a well-documented, context-dependent role in breast cancer development. In normal and premalignant cells, it acts as a tumor suppressor. By contrast, during the malignant phases of breast cancer progression, the TGF-beta signaling pathway elicits tumor promoting effects particularly by driving the epithelial to mesenchymal transition (EMT), which enhances tumor cell migration, invasion and ultimately metastasis to distant organs. The molecular and cellular mechanisms that govern this dual capacity are being uncovered at multiple molecular levels. This review will focus on recent advances relating to how epigenetic changes such as acetylation and methylation control the outcome of TGF-beta signaling and alter the fate of breast cancer cells. In addition, we will highlight how this knowledge can be further exploited to curb tumorigenesis by selective targeting of the TGF-beta signaling pathway.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据